Literature DB >> 27559622

Insights into the definition of terms in European medical device regulation.

Marco Racchi1, Stefano Govoni1, Adele Lucchelli1, Laura Capone2, Emiliano Giovagnoni2.   

Abstract

INTRODUCTION: Medical devices comprise apparatus/instruments, software, and materials with therapeutic activities obtained by principal mechanisms of action different from pharmacological, immunological and metabolic, which are proper of medicinal products. In this context the key for the distinction between medicinal products and devices lies in the correct interpretation of these terms, which, although defined in a guideline, are still not univocally interpreted. Areas covered: This article discusses the definitions of pharmacological and non-pharmacological mechanisms of action, such as the chemical and physical means. The aim is to give insights on the correct definition these terms in order to contribute to build the desired synergy between scientific and regulatory fields and promote a correct interpretation of the European regulatory framework as well as sustainable health and innovation. Expert commentary: We propose a series of definitions and a method to interpret those definitions within possible decision tree paradigm. Specifically, we propose to define the difference between the terms 'action' of a medical device compared to the 'mechanism of action' of such device. In any decisional procedure the correct interpretation of these and other correlated terms is needed to correctly assess whether a substance is a medicinal product or a medical device.

Keywords:  Medical device regulation; immunological mechanism; mechanism of action; metabolic mechanism; pharmacological mechanism; regulatory definitions; therapeutic effect

Mesh:

Year:  2016        PMID: 27559622     DOI: 10.1080/17434440.2016.1224644

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  3 in total

Review 1.  Advances and limitations of drug delivery systems formulated as eye drops.

Authors:  Clotilde Jumelle; Shima Gholizadeh; Nasim Annabi; Reza Dana
Journal:  J Control Release       Date:  2020-02-03       Impact factor: 9.776

Review 2.  Left ventricular restoration devices post myocardial infarction.

Authors:  Tom Hendriks; Remco A J Schurer; Lawien Al Ali; Ad F M van den Heuvel; Pim van der Harst
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

3.  Combination of Hyaluronan and Lyophilized Progenitor Cell Derivatives: Stabilization of Functional Hydrogel Products for Therapeutic Management of Tendinous Tissue Disorders.

Authors:  Alexis Laurent; Alexandre Porcello; Paula Gonzalez Fernandez; Annick Jeannerat; Cédric Peneveyre; Philippe Abdel-Sayed; Corinne Scaletta; Nathalie Hirt-Burri; Murielle Michetti; Anthony de Buys Roessingh; Wassim Raffoul; Eric Allémann; Olivier Jordan; Lee Ann Applegate
Journal:  Pharmaceutics       Date:  2021-12-19       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.